nccn-acute-myeloid-leukemia

name	nccn-acute-myeloid-leukemia
description	NCCN clinical practice guideline navigation for Acute Myeloid Leukemia. Use when a clinician needs treatment decisions, staging, workup, or evidence for Acute Myeloid Leukemia based on NCCN Guidelines version 3.2026.
metadata	{"author":"nccn-skill-generator","version":"3.2026","source":"NCCN Clinical Practice Guidelines in Oncology","guideline":"Acute Myeloid Leukemia"}
license	See NCCN terms of use

NCCN Guidelines: Acute Myeloid Leukemia

Clinical decision support derived from NCCN Clinical Practice Guidelines in Oncology. Version 3.2026.

Disease Subtypes

Evaluation for AML

• Algorithm: Evaluation for AML -- Staging, workup, and treatment pathways

APL: Classification and Treatment Recommendations

• Algorithm: APL: Classification and Treatment Recommendations -- Staging, workup, and treatment pathways

APL: Low-Risk Treatment Induction and Consolidation Therapy

• Algorithm: APL: Low-Risk Treatment Induction and Consolidation Therapy -- Staging, workup, and treatment pathways

APL: High-Risk Induction and Consolidation Therapy

• Algorithm: APL: High-Risk Induction and Consolidation Therapy -- Staging, workup, and treatment pathways

APL: Post-Consolidation Therapy and Monitoring

• Algorithm: APL: Post-Consolidation Therapy and Monitoring -- Staging, workup, and treatment pathways

APL: Therapy for Relapse

• Algorithm: APL: Therapy for Relapse -- Staging, workup, and treatment pathways

AML: Risk Group and Induction (Intensive Induction Eligible)

• Algorithm: AML: Risk Group and Induction (Intensive Induction Eligible) -- Staging, workup, and treatment pathways

AML: Follow-up and Reinduction After Cytarabine-Based Induction

• Algorithm: AML: Follow-up and Reinduction After Cytarabine-Based Induction -- Staging, workup, and treatment pathways

AML: Risk Group and Induction (Intensive Induction Ineligible or Declines)

• Algorithm: AML: Risk Group and Induction (Intensive Induction Ineligible or Declines) -- Staging, workup, and treatment pathways

AML: Follow-Up After Induction Therapy with Lower Intensity Therapy

• Algorithm: AML: Follow-Up After Induction Therapy with Lower Intensity Therapy -- Staging, workup, and treatment pathways

AML: Consolidation Therapy (Intensive Induction Eligible)

• Algorithm: AML: Consolidation Therapy (Intensive Induction Eligible) -- Staging, workup, and treatment pathways

AML: Maintenance Therapy

• Algorithm: AML: Maintenance Therapy -- Staging, workup, and treatment pathways

AML: AML Surveillance and Therapy for Relapsed/Refractory Disease

• Algorithm: AML: AML Surveillance and Therapy for Relapsed/Refractory Disease -- Staging, workup, and treatment pathways

AML: Therapy for Relapsed/Refractory Disease

• Algorithm: AML: Therapy for Relapsed/Refractory Disease -- Staging, workup, and treatment pathways

AML: ELN Risk Stratification by Biological Disease Factors

• Algorithm: AML: ELN Risk Stratification by Biological Disease Factors -- Staging, workup, and treatment pathways

AML: Evaluation and Treatment of CNS Leukemia

• Algorithm: AML: Evaluation and Treatment of CNS Leukemia -- Staging, workup, and treatment pathways

AML: Monitoring During Intensive Therapy

• Algorithm: AML: Monitoring During Intensive Therapy -- Staging, workup, and treatment pathways

AML: Measurable (Minimal) Residual Disease Assessment

• Algorithm: AML: Measurable (Minimal) Residual Disease Assessment -- Staging, workup, and treatment pathways

BPDCN: Introduction

• Algorithm: BPDCN: Introduction -- Staging, workup, and treatment pathways

BPDCN: Evaluation/Workup

• Algorithm: BPDCN: Evaluation/Workup -- Staging, workup, and treatment pathways

BPDCN: Treatment

• Algorithm: BPDCN: Treatment -- Staging, workup, and treatment pathways

BPDCN: Surveillance and Treatment for Relapsed/Refractory Disease

• Algorithm: BPDCN: Surveillance and Treatment for Relapsed/Refractory Disease -- Staging, workup, and treatment pathways

BPDCN: Evaluation and Treatment of CNS Disease

• Algorithm: BPDCN: Evaluation and Treatment of CNS Disease -- Staging, workup, and treatment pathways

Abbreviations

Shared Resources

Summary of the Guidelines Updates

• Summary of the Guidelines Updates -- Shared clinical resource

APL: Principles of Supportive Care for APL

• APL: Principles of Supportive Care for APL -- Supportive care guidelines

APL: Principles of Systemic Therapy for APL

• APL: Principles of Systemic Therapy for APL -- General treatment principles

AML: Principles of Radiation Therapy

• AML: Principles of Radiation Therapy -- Radiation therapy guidelines

AML: General Considerations and Supportive Care for Patients with AML

• AML: General Considerations and Supportive Care for Patients with AML -- Supportive care guidelines

AML: Principles of Systemic Therapy for AML

• AML: Principles of Systemic Therapy for AML -- General treatment principles

AML: Principles of Supportive Care for AML

• AML: Principles of Supportive Care for AML -- Supportive care guidelines

AML: Response Criteria Definitions for Acute Myeloid Leukemia

• AML: Response Criteria Definitions for Acute Myeloid Leukemia -- Standardized response assessment criteria

AML: Principles of Venetoclax Use with HMA or LDAC

• AML: Principles of Venetoclax Use with HMA or LDAC -- General treatment principles

BPDCN: Principles of BPDCN

• BPDCN: Principles of BPDCN -- General treatment principles

BPDCN: Principles of Supportive Care for BPDCN

• BPDCN: Principles of Supportive Care for BPDCN -- Supportive care guidelines

---

Citation: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3.2026. National Comprehensive Cancer Network. Available at nccn.org.

This skill references copyrighted NCCN content. Refer to nccn.org for the authoritative source and full terms of use.